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Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are 
variable. Ulcerative colitis is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and 
immune suppressants are used for the therapy of ulcerative colitis. The mainchallenges in the management of thediseaseare drug-related side-
effects and local targeting. To overcome these challengesprobiotics and micro and Nanoparticulate system0Tauspicious
Keywords: Inflammatory chronic disease, Probiotics, Micro and Nanoparticulate 
approaches to overcome 
drug-related adverse side effects and local targeting.Upon ingestion, the probiotics can result in beneficial health effects. Probiotics and micro and 
nanoparticulate approaches for suitable targeting and overcome the drug-associated side effect. Probiotics are mainly used as gut modulators but 
are also nowadays explored for their use in ulcerative colitis.The current therapeutic goals are to achieve clinical remission along with mucosal 
healing, avoidance of complications such as side effects of the drug and to improve the quality of life. The use of probiotics to increase the health of 
the intestine and used to block or manage intestinal disorders. They may prevent the induction of inflammatory reactions. Probiotics must be 
inspected for efficacy in the prevention and management of a wide spectrum of gastrointestinal diseases, like antibiotic-associated diarrhea.Micro 
and Nanoparticulate drug delivery system has been achieving huge importance for targeting of the drug to colon locally at a controlled and 
sustained rate.  
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INTRODUCTION 
IBD is a disease of the gastrointestinal tract and it isidentified by 
unrestricted inflammation caused by unsuitable and constant 
activation of the mucosal immune system.Ulcerative colitis and 
Crohn’sdisease are the different types of inflammatory bowel 
disease (IBD), which are very common, with associated significant 
morbidity and mortality [1,2]. While the main reasons are mostly 
undetermined of thepathogenesis of IBD but the factors related to 
the environment and genetic vulnerability are found to be 
associated with it[3].Ulcerative colitis is chronic inflammatory 
disorders found in the intestinal tract that causes the life-
threatening issue and have an increasing occurrence worldwide [4]. 
The small intestine and large intestine or colon are the major areas 
involved in the IBD, which are manifested by the persistent 
inflammation in certain areas of the mucosa[5]. It is determined by 
intermittent rectal bleeding, diarrhoea, rectal urgency, 
andtenesmus[6]. Molodeckyet al. (2010) studied In Western Europe, 
Asia, and North America;this disease has an annual occurrence of 
approximately 24.3 per 100,000 populations every year, 6.3 per 
100,000 per year, and 19.2 per 100,000 populations every year, 
respectively.IBD is becoming a world disorder because of its 
increasing occurrence and prevalence of it concerning time. There is 
a very lower occurrence in Africa, South America, and Asia[7]. It has 
been predicted that more than 1 million individuals suffered from 
IBD intheUS, out of which 100,000 are children. IBD is in 5th rank 
amid the most common gastrointestinal disorder. 
Epidemiology 
The occurrence and prevalence of ulcerative colitis have been 
expanding over time worldwide. Ulcerative colitis is mainly 
relatedto recurrent attacks with complete remission of symptoms. 
Kim et al. (2017) studied shownthe increased incidence of the 
disease is more (three to six-fold more) in Jewish and it is more 
common in Caucasians than in black. In Western Europe occurrence 
of approximately 6 to 8 cases per 100,000 populations and the USA, 
and an estimated occurrence of about 70 to 150 per 100,000 
populations. Within Europe, it seems a variance in ulcerative colitis 
incidence; with the eastern countries have low incidence than in 
western and in northern countries. The possibility of progression of 
ulcerative colitis in children of animmigrantfrom low-occurrence to 
high-occurrence state is the same as non-immigrants. In the world, 
IBD is becoming a big problem because of its increasing occurrence 
and widespread of itsconcern for time. Theincidence in Africa, Asia, 
and South America is very low[8,9]. In the United States, it has been 
predicted that 100,000 children are affected by IBD in theUS out of 1 
million people. 
Etiology of ulcerative colitis 
The precise cause of ulcerative colitis is not known, but some factors 
that are related to the disease, including family history, use of oral 
contraceptives, genetic, Gut/environmental, psychosomatic, 
autoimmune, epidemiological are responsible.An autoimmune 
condition stimulated by colonic bacteria resulting in inflammation of 
the gastrointestinal tract is possibly called Ulcerative colitis.Family 
history is there in around25-40%of children; the people about to 
wth concerning anindividual with Chrons disease are 17-35 times 
more likely to develop ulcerative colitis than the general population. 
A combination of factors, including abnormal mucosal immune 
responses, intestinal epithelial dysfunction, and defects of host 
interactions with intestinal microbes, can contribute to CD[10]. 
Environmental factors consist of immune interactions, bacterial 
infections, and epithelial barrier functions. Epidemiological studies 
consist of nutritional behavior, smoking habits, ingestion of drugs, 
hormonal conditions, variations resulting from different climates, 
and changes due to social conditions. Hygiene theory suggests that 
the decline in enteric infections in developed countries has caused 
insufficient progress of the dictatorial processes that mucosal 
immune responses are bound[11].The inflammatory factors can be 
investigated through different cell signal pathways, inflammatory 
mediators such as tumor necrosis factor α (TNF-α), Interleukin-6, 
Interleukin-1, Interleukin-4, Interleukin-12, Interleukin-11 and 
Interleukin-4, and Eicosanoids profiles[12]. 
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Fig.1: Etiologic factors in IBD 
 
Fig. 1[13] shows the etiologic factors in IBD. Chronic inflammation 
resulted from the production of reactive oxygen species produces 
dysplasia, which can turn into CAC, i.e., colitis-associated colorectal 
cancer, which is a critical type of ulcerative colitis. Therefore, with 
ulcerative colitis, the high possibility of colon cancer in patients is 
there[14]. The mucosal layer of the colon is the region where the 
inflammation is confined. The rectum is always involved, with 
inflammation expended proximally in a confluent fashion.In 
opposition, theCD is not limited to a restricted region and can be 
found in any part of GIT, and the inflammation can be asymmetrical, 
transmural, and segmented[15]. 
Pathophysiology of ulcerative colitis 
Pathogenesis of ulcerative colitis remains unknown, in current years 
several some many findings conclusion point to an over incentive or 
insufficient regulation of the mucosal immune system as a crucial 
pathophysiologic pathway, and then particular emphasis can be given to 
the analyses of immunologic reactionsormucosal inflammation. Several 
factors of ulcerative colitis that result in primary immunological 
disorders or there are doesn’t appropriate pathological immunological 
reactions to an environment e. g, commensal intestinal microorganisms. 
The first main cause is the deregulation of the immune system, which 
resultsinuncontrolledimmune responses to usual microflora. 
 
 
Fig.2: Mechanism of UC via the NF-κB mechanism 
 
In maximum (i.e. 95%) cases, deregulations of the immune system 
expend directly from the rectum in a continuous pattern involving 
part or every part of the colon. A second cause is the epithelial cell 
abnormalities and alters in the content of gut microflora that 
facilitates an unusual mucosal immune response[16]. A third cause 
is reducedgene expression i.e., alteration of the gene that is 
CARD15/NOD2[17].Ulcerative colitis is a chronic condition that 
contains large intestine and colon, where the entire organ or a 
portion of the gastrointestinal is affected by inflammation. 
Ulcerative Colitis is the inflammatory bowel disease which 
continualinflammation and ulceration which expend from the 
rectum towards the caecum and is normallyrelated to extra IL-13 
producing where, Crohn's disease is related tothe abundant 
production of IL-12/IL-23 and IFN-γ/IL-17, it usually involves part 
of ileum and colon where discontinuous ulceration and 
inflammation including granulomas occurs [18]. Fig. 2[19] shows 
the mechanism of UC by NF-Κbmechanism. Unusually increased 
intestinal permeability is oneof the factors that caused ulcerative 
colitis and that will result in disease continuation, which can be 
reported by some authors. Thus breaking down the barrier function 
of epithelial wall conduct to increase the permeability of mucosa for 
luminal antigens, bacteria or microorganisms, and loss of water and 
electrolytes by activating the inflammatory process.Due to breakage 
of the barrierfrom the epitheliumwater,and various electrolytes 
have been lost Incorporation of this, the lost polarity of damaged 
intestinal cells that results in apical expression of the transferrin 
receptor protein, whose appearance is mainly increasedon apical 
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and basolateral sites of enterocytes in the inflamed mucosa of IBD 
patients. 
Signs and symptoms of ulcerative colitis 
The main symptoms of ulcerative colitis (UC) includepain, 
discomfort and diarrhea with blood(table 1). Fever and weight loss 
occursometimes.Extraintestinal symptoms can be an initial 
expression or can occur subsequently in the duration of the illness. 
In proctitis, occasionally, obstipation can be the initial 
symptom.Weight loss, tachycardia, rectal bleeding, and bowel 
inflation are significantsymptoms. Ulcerative colitis is divided into 
various classes i.e.,distal, extensive,ulcerativeproctitis. Meier et al. 
(2011) have studied which briefly explains that ulcerative colitis is 
given in fig. 3 [20]. Around eighty percent of the patients suffer from 
proctitis, and extensive colitis is found in 20% of patients. 
 
Table1: Initial symptoms of ulcerative colitis 
S. No. Symptoms % frequency Referances 
1. Diarrhoea 96.4 % [20] 
2. Blood in stool 89.3 % [20] 
3. Pain 81.3 % [20] 
4. Generally unwell 40.2 % [20] 
5. Arthralgia 27.7 % [20] 
6. Fever 20.5 % [20] 
7. Weight Loss 38.4 % [20] 
8. Fever 20.5 % [20] 
9. Skin Changes 20.5 % [20] 
10. Loss of appetite 15.2 % [20] 
11. Ophtalmopathies 7.1 % [20] 
12. Nausea 6.3 % [20] 
 
However,proximal extension results late in around 50% of patients 
with proctosigmoiditis, and in otherpatients, the opposite occurs. A 
change in the area of the disorder should arise new symptoms. The 





: A schematic diagram for ulcerative colitis 
Table 2: Drugs used in the treatment of ulcerative colitis 
Drug 
type 
Drug name Available 
routes 














Sulfasalazine: 2-4 g 
Mesalamine: 1.6-2.4 
g Mesalamine:  






















Prednisone: 40-60 mg 
Budesonide: 9 mg 
Methylprednisolone: 
40-60 mg daily  


































Infliximab: 5 mg/kg 
weeks 0, 2, and 6 
Adalimumab: 160 mg 
week 0, 80 mg week 2 
Infliximab: 5 mg/kg 
every 8 wAdalimumab: 
40 mg every 2 
wGolimumab: 100 mg 
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Golimumab: 200 mg 
week 0, 100 mg week 2 
Drugs used in the management of ulcerative colitis 
Ulcerative colitis relies on the extremity of the disease, its subtype, 
patient preference. Most frequently used drugs for its cure and 
management are an anti-inflammatory agent which mostly includes 
5-aminosalicylates like olsalazine, mesalazine, and balsalazide, 
which can treat slightly to average attacks and can sustain remission 
in UC and immunosuppressive agents which includes azathioprine, 
6-mercaptopurine, methotrexate, cyclosporine, tacrolimus 
calcineurin inhibitors. Other categories of drugs include 
Corticosteroids, like prednisolone and anti–TNF-α-antibodies for 
ordinary to acute or serious conditions of IBD [21]. Table 2 shows 
the different drugs used in the treatment of ulcerative colitis. 
Aminosalicylates 
Sulfasalazine is the first-class drug of antibiotics. For the 
management of ulcerative colitis Oral 5-aminosalicylic acid (5-ASA) 
is taken.Mesalamine (5-ASA) is usually absorbed from the upper 
region of the intestine; particular delivery of drugs into the colon 
may be amoreacceptablemethod of drug delivery with fewerside 
effects and more potency. Due to side effects in those with sulfa 
allergy and nausea, newer forms of 5-ASAs were created specific for 
its activity on the GI tract. The mechanism of action of 5-Amino 
salicylates includes the stimulation of class of nuclear receptors, 
which mainly include cell proliferation and inflammation. It helps in 
decreasing the production of chemoattractant leukotriene and slows 
down the cellular release of interleukin-1 and 2[24]. Wanget al. 
(2016) have studied 5-ASA Common side effects like flatulence, 
nausea, abdominal pain,diarrhea, headache, dyspepsia, 
nasopharyngitis[25].Management of mesalamine usingacombination 
of rectal and oral provides complete relief of distal UC than rectal or 
oral therapy alone[26]. 
Corticosteroids 
These drugs act via glucocorticoid receptor in the cell nucleus and 
immune response modulates but due to the steroidal nature of these 
drugs, they can improve corticoid resistanceandcorticoid 
dependency,which their maximum applicability in UC[27]. These 
drugs are used for mild to common conditions of UC. But in the acute 
type of IBD and for patients who do not show any effect to 
corticosteroids, Immunosuppressive drugs like azathioprine, 6-
mercaptopurine, methotrexate, cyclosporine, tacrolimus, etc. are the 
next line of drugs and play an important part in the treatment IBD. 
But the safety profile of this treatment is still an issue [28].  
Thiopurines 
The thiopurines, 6-MP and AZA have been said to sustain remission 
in both CD and UC. AZA is the prodrug to 6-MP as it is metabolized to 
6-MP. Both drugs are thiopurine analogs that work through 6-
thioguanine nucleotide (6-TGN), which is the active metabolite, 
which in turn stops the synthesis of DNA and RNA and also the 
apoptosis of T-cell [29,30]. AZA/6MP inhibits purine synthesis and 
ultimately DNA and RNA synthesis. They also stop T-and B-
lymphocyte multiplication. However, the precise mode of action at 
UC is not known.They can be used to cause and retain remission in 
UC with effectiveness rates of 60–70%. They can reduce the dose or 
stop steroids in patients who have better with steroids and chronic 
active disease not completely controlled with steroids[31]. 
Anti-tumor necrosis factor therapy 
Infliximab is a chimeric monoclonal antibodythatis used against 
tumornecrosis factor-alpha(TNF-α) and also used in the 
management of autoimmune diseases.For patients with average-to-
acute UC who are intolerant of mesalazine (5-ASA) products and 
immune modulators, infliximab is used for remission induction. UC 
patients failed mesalamine and immune modulators therapy, then 
Infliximabcan be used for management of remission in UC patients. 
The use of infliximab in ulcerative colitis patients whose therapy is 
based on steroids is unclear. Infliximab can be used in acute steroid-
resistant in ulcerative colitis patients who are unwilling to undergo 
surgery. The cases of hepatosplenic lymphoma have been described 
in younger patients on infliximab who were on relatedimmune-
suppressive agents [32,33].  
Challenges in the maintenance and treatment of ulcerative colitis 
Many drugs are available for the therapy of ulcerative colitisi.e. 5-
aminosalicylic acid, oral or systemic corticosteroids, immune 
modulator, etc. but these drugs are associated with many serious side 
effects after long-term use or have a certain disadvantage or not 
suitable for the use in some patients. Reduction of drug-related side-
effects is the main challenge of therapy in ulcerative colitisi.e. (weight 
loss, rectal bleeding, anemia, tachycardia, and bowel distension by 
drug delivery to the colonwhich is site-specific[34]. Kimet al. (2006) 
have studied to design a delivery system, which delivers the maximum 
amount of drug to the specific site at the right period timein the body 
that increases efficacy, compliance is a great [35]. There are numbers 
of agents taken for the therapy of ulcerative colitis diseases but they 
show adverse effects like diarrhoea, peptic ulcers,nephron and 
hepatotoxicity, vomiting, glaucoma, Cushing's syndrome,etc. [36-38]. 
To target the drugs,particularlyto the colonic part of GIT is the main 
challenge[39]. Synthetic drugs have variousdrawbacks and for this 
reason, safeandefficacious drug treatment for the UC is the problem. 
The damage to skeletal and growth development is because of the 
absence of balanced nutrition is another problem for children with 
IBD. To solve these difficulties, proper nutrition and appropriate anti-
inflammatory therapy are the best options. 
Role of microparticlesand nanocarrierin ulcerative colitis 
Microparticles and Nanocarrier systems are used for the targeted 
type of drug delivery for the management of ulcerative 
colitis.Microparticles are suitable for a wide variety of drug delivery 
applications, and they offer many advantages. 
• Their small particle size offers improved reproducibility in the 
drug release mechanism.  
• They offer improved control over the release rate of the drug.  
• A microparticle offers immediate, modified, delayed, pulsed, 
sustained, and extended-release.  
• They allow the preparation of dosage forms for colon delivery 
through the use of coatings designed.  
• Their reduced particle size gives them the potential to improve 
bioavailability. 
The major motive of this delivery system is to target the high 
concentration of active ingredients to the site in the inflamed 
intestinal tissues to enhance the therapeutic efficacy and minimizing 
the side effects[40]. Micro and Nanoparticle systems providea 
selective drug targeting to the specific site with alossin the needed 
efficacious drug dose and side effects[41].
The major step in this direction is preparing pharmaceutical dosage 
forms with reduced sizes, which will enhance the time of their 
residence in the colonic part. The most common characteristic of 
IBD is diarrhea that causes the streaming of the dosage form (rapid 
transit of large dosage forms). By decreasing the size of dosage 
forms (e. g. pellets) the enhancement in the retention timecan be 
done. Further,the decrease in size to micrometer range will help 
toreduce the streaming effect (and thereby increase the residence 
time)and also helps in enhancing the bio-distribution of drug 
molecule[42,43].Lately, many innovative ideas have been explored 
for the management of IBD. The main motive behind 
thedevelopment of these targeted drug delivery systems was to 
reachsite-specific transport of active moieties to the inflamed tissue. 
These drug carrier systems not only prevent degradation of 
activemoieties against various physiological changes happening 
during IBD but also increase the therapeutic effectiveness and lessen 
the incidence of systemic adverse drug reactions. Research and 
development in the treatment of IBD are observing steady-state 
So the formation of a novel 
site-specific drug delivery system that will increase the drug release 
inthe inflamed tissues without causing any harm to normal tissues 
and then decrease the side effects of the drug is needed. 
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progress in terms of thedevelopment of upgraded and smart drug 
delivery systems, and highly effective therapeutic agents. One can 
say that the idea of attaining effective and site-specific targeting for 
the treatment of IBD will soon be able to knock the doors of reality.  
Mechanism of uptake of nanocarriers/microcarriers 
The mechanism of uptake of nanocarriers/microcarriersforsite-
specific drug delivery is depending upon the full information of the 
mechanism of disease and drug. In some studies, it has been stated 
that for ulcerative colitistreatment, microparticles range should be 
10–300 µm to target specifically to the inflamed region of the colon. 
Carrier selection is very important for a particular drug i.e. either 
hydrophilic or lipophilic and also depends on the disordered 
situations as well as on the physicochemical nature of thedrug.The 
optimal particle size should be between 4 to 15 µm for improved 
localization and increased theresidence time of the drug at the site 
of inflammation [44-46]. To attain high localization in Payer’s 
patches, intestinal lymphoid tissue, and lamina propria, there is the 
need to overcome such barrier/layer. In the case of UC, as the 
disease severity increases, the protective mucus layer starts 
becoming thinner. This pathophysiology of the mucus layer 
increases the mucosal permeability and helps in the proper location 
at its inflamed sites. Size-dependenttranslocation of MP and NP 
across colonocytes in the healthy GI tract containsfig. 4Lamprechtet 
al.(2001) shows that the mechanism of nanocarriers in ulcerative 
colitis thatnanocarriers system systems to target the inflamed 
mucosa are a promising strategy in ulcerative colitis treatment[46].
 
 
Fig.4: Show the mechanism of nanocarriers uptake in ulcerative colitis 
 
Reducing the particle size of drug delivery systems is believed to 
increase colonic residence time but can also provide additional benefits 
for IBD therapy, such as a selective accumulation in inflamed tissues. 
Nanocarriersare taken up by an increased number of immune-related 
cells in active inflammation and to suppress inflammation via multiple 
pathways, like inhibiting the production of pro-inflammatory cytokines 
(i.e., TNF-a, IL-1b or IL-8). In some earlier studies, the different carriers 
system used in ulcerative colitis is shown in table 3. 
 
Table 3:Different carrier system used in ulcerative colitis 






No Systemic toxicity was observed and great potential application in inflammatory 
bowel disease. 
[48] 
Microparticles Increase therapeutic efficiency, mucoadhesive and controlled release. [49] 
Chitosan-ca-alginate 
microparticles 
5-ASA loaded microparticles have the potential for intensive mucoadhesion and 




Drug targeting, biocompatible, low toxicity. [51] 
Cyclosporine Polymeric nanocarriers  Minimizing systemic exposure and associated adverse effect. [52] 
Lipid nanoparticles Enhancing efficacy and reducing the risk of nephrotoxicity and decrease renal 
damage. 
[53] 
Eudragit S 100 solid 
nanomatrix 
Improved nephrotoxicity and increase bioavailability. [54] 
Prednisolone Conjugate microspheres Eudragit-coated Ch-SP-MS were considered potentially suitable for in vivo or 
practical application as a specific delivery system of PD to IBD sites 
[55] 
Silica microparticles Increase bioavailability by sustaining the drug release and enhancing drug 
permeability. 
[56] 
Microspheres Reduce toxicity, Ch–SP-MS/Eul reduced 
significantly the thymicatrophy caused by PD.  
[57] 
 Budesonide  Chitosan coated ca-
alginates microparticles 
Eudragit coating has successfully sustained the release of BDS in the upper GIT 
(pH 2.0 and 6.8) while providing the potential for efficient release of BDS in the 
colon (pH 7.4). 
[58] 
Microparticles Site-specific and controlled delivery and reduce toxicity. [59] 
Vancomycin Chitosan-based micro 
and nanoparticles 
Micro and nanoparticles improve the release in the colon [60] 
Glucocorticoster Collagen microparticles The drug was not influenced by the pH of the release medium. Binding to the [61] 
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oids particles did not affect the stability of hydrocortisone. Collagenmicroparticles can 
be successfully used as a carrier system for lipophilic steroids. 
Role of probiotics in thetreatment of ulcerative colitis 
Probiotics are ‘live microorganisms which when given in sufficient 
quantity, are beneficial to the host.Probiotics are microorganisms 
that we take into our bodies to support our health. Commonly, 
they're strains of bacteria that can help improve our digestion.The 
health benefits of Probiotics are shown in fig. 5 [61]. Probiotics are 
that rare supplement from which almost everyone can benefit. 
Probiotics assist with a lot of health concerns, such as healthy 
digestion, healthy metabolism, and even increased weight loss. A 
poor diet, too much stress, and a lifetime of antibiotics have likely 
disposed of the majority of the good bacteria.The identification of 
the microbial environment and cytokine expression as key 
components of intestinal mucositis, probiotics represents a 
promising therapeutic option. When probiotics are administered in 
sufficient numbers, they can provide beneficial physiologic or 
therapeutic activities. Bacteria can be derived from various sources, 
such as cultured.food and normal human microbiota, but must 
certain criteria included complete identification at genus, species, 
and strain level;antimicrobial substances; safety for consumption; 
may apply probiotic properties is impressive. Some are listed in 
table 4. For nutrition,the strains categorized as lactic acid bacteria 




Fig.5: Health benefits of probiotic 
 
Table 4: Microorganisms commonly used as probiotics 
Lactobacilli Bifidobacteria Others References 
L. CaseiShirota 























Lactobacilli are Gram-positive, non-spore-forming, and non-
flagellated rods or coco bacilli, aerotolerant, fastidious, acid-tolerant, 
and strictly fermentative[63].The different probiotic strain has 
adifferent ability, even within the same species, it is different. 
Different strains of the same species are always distinct and may 
have different areas of attachment (site-specific), specific 
immunological effects, and activity on a healthy vs. an inflamed 
mucosal milieu may be different from each other.The research on 
probiotic today aims at the characterization of microbiota in each 
individual, analyzing the species constitution as well as the 
numberofdifferent bacteria in the intestine. The objective is to learn 
to comprehend host-microbe interactions inside the gut, microbe-
microbe interactions inside the microbiota, and the joint 
healtheffects of these interactions. The aim is to study the 
microbiota in the nutritional management of gut-related problems 
and as an origin of new microbes for future probiotic 
bacteriatherapyapplications. This will finally include organisms 
notably isolated to provide site-specific actions in disorders like 
IBD[64]. 
Probiotics alter the function of the mucosal immune system making 
it more anti-inflammatory and less pro-inflammatory;especially, 
probiotics can inspiredendritic cells to make them less responsive 
and less reactive to bacteria within the lumen. Probiotics increase 
the production of mucus and the patient will finally have a thicker 
layer, which saves the invasive bacterias. Probiotics supplements 
may lower the side effect of individual drugs. DifferentProtective 
actions of probiotics show in table 5. 
 
Table 5:Protective action of probiotics 
Microflora Action of microflora Reference 
Bifidobacteria species Reduced incidence of neonatal necrotizing enterocolitis 
Balancing intestinal microflora, treatment of viral diarrhoea 
[66] 
Lactobacillus strains Improved mucosal immune function, mucin secretion, and prevention of disease. 
Lactose digestion improved decreased diarrhoea and symptoms of intolerance in lactose 
intolerant individuals, children with diarrhea, and in individuals with short–bowel syndrome. 
[67] 
LactobacillusAcidophilus Significant decrease of diarrhoea in patients receiving pelvic irradiation. [68,69] 
Lactobacillus Plantarum Lowered serum cholesterol levels.Reduced incidence of diarrhoea in daycare centers when 
administered to only half of the children.Especially effective in reducing inflammation in 
inflammatory bowel; enterocolitis in rats, small bowel bacterial overgrowth in children, 
pouchitis.Reduced pain and constipation of irritable bowel syndrome. 
[70-72] 
Lactobacillus rhamnosus Enhanced cellular immunity in healthy adults incontrolled trials. [73] 
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Escherichia coli Nissle 1917 (EcN) Anti-inflammatory effect and prevent relapse.  [74,75] 
Streptococcus The Strain of Streptococcus thermophilushas also reduced the risks of AAD (antibiotics-
associated diarrhea). 
[76] 
Probiotics and ulcerative colitis 
Escherichia coli Nissle 1917 and Saccharomyces boulardiiwere used 
as probiotics. Probiotics have living microorganisms that 
providehealth benefitsto the host.EscherichiacoliNissle 1917 
established therapy with mesalazine in patients with 
ulcerativecolitis.It was seen that the probiotic drug E. coliNissle 1917 
showstheeffectiveness and was declared to be safe to maintain 
remission and was equal to mesalazine in patients with ulcerative 
colitis. The efficacy of probiotic therapy further tells about 
thepathogenetic importance of the enteric flora [76]. 
Fábregaet al. (2017) have shown theIntestinal Anti-inflammatory 
Effects from Escherichia coli Nissle 1917 in DSS-Experimental Colitis 
was studied in Mice. Oral administration of purified EcN OMVs 
(5µg/day) significantly reduced DSS -induced weight loss and 
ameliorated clinical symptoms and histological scores. This study 
showed that EcN OMVs can mediate the anti-inflammatory and 
barrier protection effects previously reported for this probiotic in 
experimental colitis[77]. 
Naidooet al.(2011) Studies have shown the significance of intestinal 
bacterial flora in the pathogenesis of inflammatory bowel disease. It 
has therefore proposed thataltering the bacterial flor a with 
probiotics will reduce the inflammatory process and stop the 
relapses in ulcerative colitis (UC)[78]. 
Pronioet al.(2008)studies that show that the period, VSL#3-treated 
patients showed a notable loss in PDAI score and a major 
enhancement in the percentage of mucosal CD4CD25high and CD4 
LAP-positive cells compared with baseline values.Different samples 
were taken at different points a significant reduction in IL-1 mRNA 
expression was seen, and a major enhancement in Foxp3 mRNA 
expression[79]. 
Zoccoet al.(2006) ware studied aminosalicylates are the mainstay of 
therapy to prevent relapse of quiescent ulcerative colitis. The rationale 
for using probiotics is based on the evidence implicating intestinal 
bacteria in the pathogenesis of this disorder. Lactobacillus GGlooks to 
be effective and safe for maintaining remission in patients with 
ulcerative colitis, and it could represent a good therapeutic option for 
preventing relapse in this group of patients[80]. 
Loren et al.(2017) investigated the therapeutic benefits of 
Lactobacillus Plantarum (CECT7484, CECT7485) and 
PediococcusAcidilactici (CECT7483)) in a murine model of colitis. 
Result suggests that the selected probiotic group significantly 
reduces colitis severity compared to untreated controls [81]Wanget 
al.(2015) has studied the main mechanisms have not been 
completelyexplained; the antioxidant activity of probiotics seems to 
play an important role in reducing inflammation. Several studies 
have reported that probiotics particularly Lactobacillus species, 
exhibit strong antioxidant activity[82]. Chauhanet al.(2010) have 
recently, Lactobacillusfermentum has been studied for use as a 
supplement in the management of inflammatory bowel disease 
(IBD). Reinforcing the effects of L. Fermentum in inflammation, 
Chauhan and coworkers assessed its antioxidative efficacy in a 
colitis mouse model. Results proposed that the selected strain of 
Lactobacillus exhibits significant antioxidant activity. Also besides, 
probiotics seem to upregulate the level of antioxidant enzymes [83]. 
CONCLUSION 
The current therapeutic goals are to achieve clinical remission along 
with mucosal healing, avoidance of complications such as side 
effects of the drug and to improve the quality of life. The use of 
probiotics to increase the health of the intestine and used to block or 
manage intestinal disorders. They may prevent the induction of 
inflammatory reactions. Probiotics must be inspected for efficacy in 
the prevention and management of a wide spectrum of 
gastrointestinal diseases, like antibiotic-associated diarrhea. There 
are many benefits to probiotics over conventional therapy, including 
various things like low cost, the fact that probiotics are improbable 
to enhance the incidence of antibiotic resistance, and the multiple 
methods by which probiotics stop pathogens, therefore limiting the 
chances for the development of resistance against the probiotic. At 
present, no microencapsulated probiotic cells exist in the market. 
Thus, the search is increasing on new delivery strategies that can 
provide therapeutic benefits to colitis suffered patients. It has been 
concluded from the above study that micro and nanoparticulate 
carrier and probiotics system appears to be the most promising 
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